<b>Background</b>: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the first-line treatment for patients with non-small cell lung cancer (NSCLC) harboring EGFR mutations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.